NASD · Healthcare · Biotechnology · USA
Kiora Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases. The company is advancing KIO-301, a small molecule designed to restore vision in patients with retinitis pigmentosa and other inherited retinal diseases. It is also developing KIO-104 for retinal inflammatory conditions and KIO-101 for ocular manifestations of autoimmune diseases.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kiora Pharmaceuticals Inc stock.
Undervalued: intrinsic value $3.08 per share, market price $0.93, margin of safety 69.8% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $3.08; the price of $0.93 is 70% below that value.
KPRX is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $3.08; the price of $0.93 is 70% below that value.
$3.08 per share (as of the 2026-11-17 close), against a market price of $0.93. That is a margin of safety of 69.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.